Refine by
Image Guided Surgery Articles & Analysis
19 news found
With years of experience in the pharmaceutical and life science sector, CD Bioparticles launched a range of near-infra-red (NIR) quantum dots that exhibit excellent optical properties and biocompatibility for biomedical imaging. Currently, CD Bioparticles has successfully synthesized a variety of NIR quantum dots, including PbS/CdS, PbS, PbSe, Ag2S, CuInS/ZnS, and CdTe/CdSe/ZnS. Quantum points ...
OnLume Inc., a Madison, Wisconsin-based medical imaging company with unique technology for improving surgical precision in the operating room, has announced the start of participation in a clinical trial combining its fluorescence-guided surgery (FGS) imaging device with a novel nerve-targeting agent. OnLume has unique FGS imaging technology to illuminate critical anatomy in real time during ...
Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser endomicroscopy platform to diagnose cancer. The combination of novel molecular imaging agents and advanced visualisation ...
Subtle Medical was awarded an NIH SBIR grant to develop an innovative artificial intelligence (AI)-powered software, SubtleIR™, which uses deep learning (DL) to reduce radiation dosage needed during fluoroscopy exams. The development of the new software is aligned with the company’s mission to accelerate access to faster, safer, and smarter medical imaging. Subtle continues to ...
ClaroNav Kolahi Inc, a subsidiary of ClaroNav Inc, is pleased to announce that it has received Chinese regulatory clearance from the National Medical Products Administration (NMPA) to market and sell its Navient Cranial model in China. Previously it had received NMPA approval for Navient ENT model. Navient, an image-guided surgical navigation system, is like a GPS for the surgeon to navigate ...
ByClaroNav
Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – Avelas Biosciences, Inc. (“Avelas” or “the Company”), a clinical-stage drug-device company pioneering the field of fluorescence ...
CARLSBAD, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the FDA 510(k) clearance of its 7D Percutaneous Spine Module for minimally invasive surgery. This represents a new application and increased functionality for its 7D Flash™ ...
OnLume Surgical, a Wisconsin-based medical device company developing novel imaging systems for use during surgery, announced the completion of its Series A funding to assist its plans for commercial launch. OnLume raised over $7 Million in this financing, adding to a $2 Million Phase II SBIR grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), awarded in ...
SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed ...
Use of pegloprastide, a fluorescent cancer marker, during surgery correctly identified cancer in up to 75% of patients who may have otherwise been candidates for a repeat (re-excision) surgery Observed re-excision rate was ~6% in patients whose surgeries included pegloprastide; current re-excision rates are estimated at 20-40% among all patients receiving an initial lumpectomy Each year in the ...
SurgiMab is proud to be a sponsor of this internationally acknowledged conference, that gathers together the best specialists of Fluorescence Guided Surgery. Don’t miss the presentations by André Pèlegrin: Antibodies, favorite tools for fluorescence-guided surgery, 02/02 at 10:30 and by Ruben Meijer: Clinical translation of novel contrast agent for image guided surgery, ...
BySurgiMab
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, today announces that the first US patient has been recruited into its on-going pivotal Phase 3 clinical trial evaluating its investigational imaging agent SGM-101 in patients undergoing colorectal cancer (CRC) surgery. ...
BySurgiMab
Jan 11, 2019 –SafeHeal, an innovator in the field of digestive surgery, has concluded its first-in-human clinical study for its novel Colovac bypass sheath in patients undergoing colorectal surgery. The single-arm 15-patient study was aimed at evaluating the safety and efficacy of Colovac in the protection of colorectal anastomosis in adult patients who were scheduled to ...
BySafeHeal
Maurice R. Ferré, MD has been appointed as chairman of Memic’s board of directors, following the company’s latest $10M investment round. Signing on as a private investor, Mr. Ferré has over 20 years of experience in the medical device industry. He currently serves as CEO and chairman of the board of directors of INSIGHTEC, which delivers incisionless surgery using ...
Jan 29, 2018 – The study will evaluate safety and efficacy of the Colovac bypass device for ostomy-free anastomosis protection following colorectal surgery SafeHeal, a leading innovator in the field of digestive surgery and developer of the Colovac device, announces today that it has enrolled the first five patients in its CE mark study. The Colovac device is a unique ...
BySafeHeal
SurgiMab and Quest Medical Imaging, a leader in the market for multispectral cameras, announced today that they have entered into a collaboration agreement for the upcoming Phase III clinical trial of Surgimab’s SGM-101 in fluorescent guided colorectal cancer surgery. Under the terms of the agreement, Quest Medical Imaging has received an undisclosed lump sum payment to provide 12 ...
BySurgiMab
OnLume Inc., a medical device company developing novel surgical imaging technology, was accepted into the SBIR Advance program sponsored by the Center for Technology Commercialization (CTC). The SBIR Advance program was created by the Wisconsin Economic Development Corporation (WEDC) to provide state match funding, training, and other resources to Wisconsin businesses to advance the ...
OnLume Inc., a medical device company developing novel surgical imaging technology, today announced support from the Small Business Innovation Research (SBIR) program to accelerate work on a fluorescence image-guided surgery (FIGS) system. OnLume received the $300,000 Phase I SBIR grant through the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for the development of ...
Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today announced that it hired Ronald Zilkowski to be Landauer's Vice President, Corporate Controller and Chief Accounting Officer, effective Tuesday, September 4, 2012. "We are pleased to add Ron ...
ByLandauer